Primary Care Programs
Emerging Strategies in the Management of Chronic Fibrosing ILD Patients Who Have Contracted COVID-19
Released on 10/28/20
Expires on 10/28/21
New Paradigms in the Prevention and Treatment of Migraine with HT1F Agonist and mAb Against CGRP Pathway or its Receptor
Released on 11/25/19
Expires on 11/25/20
New Horizons in Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes with SGLT-2, GLP-1 RAs and DPP-4 Based Therapies
Released on 6/14/19
Expires on 6/14/20
Changing Landscape of GLP-1 Receptor Agonists on Glycemic Control, Weight Reduction and Cardiovascular Outcomes in Individuals with Diabetes
Released on 6/12/19
Expires on 6/12/20
Changing Landscape of Treatment Options for Migraine with Monoclonal Antibodies Targeting Calcitonin Gene-related Peptide (CGRP) Pathway or its Receptor
Released on 3/22/19
Expires on 3/22/20
Emerging Newer Therapies in the Management of Lung Function, Exacerbations, Safety and Tolerability in Patients with COPD
Released on 8/9/18
Expires on 8/9/19
Emerging Anti-Interleukin 5 (IL-5) and IL-5Ra Based Biological Therapies: Efficacy, Safety and Future Perspectives in Severe Eosinophilic Asthma
Released on 7/12/18
Expires on 7/12/19
Emerging Interleukin-5 (IL-5) or its Receptor (IL-5R) Monoclonal Antibody Based Biological Therapies for Severe or Poorly Controlled Asthma
Released on 6/29/18
Expires on 6/29/19
Emerging Strategies in the Diagnosis and Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Released on 6/19/18
Expires on 6/19/19
New Era in the Lipid Lowering Treatment with PCSK9 Inhibitors (Evolocumab and Alirocumab) in Patients with Atherosclerotic Cardiovascular Disease and Familial Hypercholesterolemia
Released on 5/11/18
Expires on 5/11/19
Emerging Strategies in the Diagnosis and Treatment of Interstitial Lung Disease (ILD)
Released on 5/10/18
Expires on 5/10/19
Emerging Strategies in the Anti–Interleukin-5 Monoclonal Antibody Based Targeted Therapies for Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Released on 2/6/18
Expires on 2/6/19
Efficacy and Safety of Fixed-ratio Combination of Insulin Degludec and Liraglutide (IDegLira) and Insulin Glargine and Lixisenatide (IGlarLixi) in Patients with Type 2 Diabetes
Released on 11/29/17
Expires on 11/29/18
Emerging Strategies in the Monoclonal Antibodies Targeting Calcitonin Gene-related Peptide (CGRP) or its Receptor in the Preventive Treatment of Migraine
Released on 11/17/17
Expires on 11/17/18
Emerging Strategies in the Management of Dyslipidemia in Patients with Atherosclerotic Cardiovascular Disease and Familial Hypercholesterolemia: PCSK9 Inhibitors (Evolocumab and Alirocumab)
Released on 10/10/17
Expires on 10/10/18
Changing Landscape of Biological Therapies for Psoriasis: Promising Efficacy of Interleukin-17 (IL-17) and IL-2 Pathway Inhibitors
Released on 9/20/17
Expires on 9/20/18
Advances in Biological Therapy of Crohn's Disease and Ulcerative Colitis
Released on 8/10/17
Expires on 8/10/18
Emerging Immunotherapeutic Strategies for Poorly Controlled Asthma
Released on 7/20/17
Expires on 7/20/18
Advances in GLP-1 Receptor Agonists, Insulins and SGLT-2 Inhibitors in the Treatment of Diabetes
Released on 5/12/17
Expires on 5/12/18
Individualized Treatment Options for Type 2 Diabetes: Comparative Effectiveness of GLP-1 Receptor Agonists on Glycemic Control, Weight Reduction and Cardiovascular Risk
Released on 4/20/17
Expires on 4/20/18
Emerging Strategies in the Treatment of Parkinson's Disease: Management of Non-Motor, Motor and Psychotic Symptoms
Released on 2/24/17
Expires on 2/24/18
Emerging Biological Therapies for Atopic Dermatitis in Children and Adults
Released on 2/15/17
Expires on 2/15/18
Biological Therapies for PsA, Osteoarthritis, SLE and Spondyloarthritis: Comparative Effectiveness Based on Treatment Profiles and ACR/EULAR Recommendations
Released on 12/15/16
Expires on 12/15/17
Emerging Interleukin5 (IL5) Antagonists Based Therapies for Eosinophilic Asthma
Released on 10/31/16
Expires on 10/31/17
Emerging Biological Therapies for Psoriasis: Promising Efficacy of Interleukin‐17 (IL‐17) and IL‐23 Pathway Inhibitors
Released on 10/28/16
Expires on 10/28/17
3rd Annual Symposium on Individualized Novel Disease-Modifying Treatment Options for Multiple Sclerosis
Released on 10/26/2016
Expires on 10/26/2017
Update on Novel Antiepileptic Drugs in Treatment of Epilepsy
Released on 9/28/16
Expires on 9/28/17
Emerging Immunotherapeutic Strategies for Poorly Controlled Asthma
Released on 7/20/2016
Expires on 7/20/2017
Update on GLP-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus
Released on 7/7/16
Expires on 7/7/17
Oncology/Hematology Programs
Changing Landscape of Treatment Options for Multiple Myeloma
Released on 10/5/20
Expires on 10/5/21
Changing Landscape of Treatment Options for Hematological Malignancies
Released on 9/28/20
Expires on 9/28/21
Current and Emerging Treatment Options for Renal Cell Carcinoma
Released on 10/10/20
Expires on 10/18/21
Current and Emerging Treatment Options for Lung Cancer and Head & Neck Cancer
Released on 7/22/21
Expires on 7/30/21
Current and Emerging Treatment Options for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Carcinoma)
Released on 6/15/20
Expires on 6/15/21
Changing Landscape of Treatment Options for Metastatic Urothelial Carcinoma
Released on 5/22/20
Expires on 5/22/21
New Paradigms in the Treatment of Relapsed Multiple Myeloma
Released on 5/3/20
Expires on 5/3/21
New Paradigms in the Treatment Options for Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML): European Perspective
Released on 4/28/20
Expires on 4/28/21
Current and Emerging Treatment Options for Lung Cancer and Head & Neck Carcinoma
Released on 12/30/19
Expires on 12/30/20
Changing Landscape of Treatment of HR+ and HER2- Metastatic Breast Cancer with PI3K and CDK 4/6 Inhibitors
Released on 12/26/19
Expires on 12/26/20
Changing Landscape of Treatment Options for ALL with CD19, CD22 Monoclonal Antibodies and AML with IDH1/2, FLT3, CD33 and Hedgehog Pathway Targeted Agents
Released on 9/17/19
Expires on 9/17/20
Evolving Landscape of Treatment for Hepatocellular Carcinoma with Multi-Targeted Tyrosine Kinase Inhibitors and Immunotherapy
Released on 6/24/19
Expires on 6/24/20
Changing Landscape of Targeted and Immunotherapies for Genitourinary Cancers
Released on 6/12/19
Expires on 6/12/20
Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma with Anti-PD-1/PD-L1 Agents
Released on 6/10/19
Expires on 6/10/20
New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia
Released on 5/13/19
Expires on 5/13/20
Optimizing Outcomes in Patients with Malignant Melanoma Treated with Targeted Agents, Checkpoint Inhibitors and Oncolytic Viral Therapies
Released on 12/30/18
Expires on 12/30/19
Emerging Novel PI3K Inhibitors, Anti-CD20 mAb and Combination Therapy Options for Follicular Lymphoma
Released on 12/30/18
Expires on 12/30/19
Changing Landscape of Treatment Strategies of TKI Interruptions, Discontinuations and Switching in Patients with Chronic Myeloid Leukemia
Released on 12/30/18
Expires on 12/30/19
Update on Treatment Options for Acute Lymphoblastic Leukemia with An Emphasis on CD19, CD22 Monoclonal Antibodies and Anti-CD19 CAR T-cell Therapy
Released on 12/30/18
Expires on 12/30/19
Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer
Released on 11/7/18
Expires on 11/7/19
Emerging Treatment Options for Genomic Subgroups of Acute Myeloid Leukemia with IDH1/2, FLT3 and CD33 Targeted Agents
Released on 10/19/18
Expires on 10/19/19
Emerging Strategies in Novel Targeted Therapies for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Bladder Carcinoma)
Released on 9/28/18
Expires on 9/28/19
Emerging Novel Anti-CD20 mAb, PI3K Inhibitors and Combination Therapy Options for Follicular Lymphoma
Released on 8/15/18
Expires on 8/15/19
Mapping the Future Treatment Options with Multitargeted TKIs and Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma
Released on 8/15/18
Expires on 8/15/19
Mapping the Current and Future Treatment Options for Advanced Soft Tissue Sarcoma Including Liposarcoma and Leiomyosarcoma
Released on 8/15/18
Expires on 8/15/19
7th Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia
Released on 7/2/18
Expires on 7/2/19
Immunotherapy with Anti-PD-1/PD-L1 Agents Are New Effective Therapies for Recurring and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Released on 6/29/18
Expires on- 6/29/19
Advances in the Treatment of Acute Lymphoblastic Leukemia with An Emphasis on CD22 and CD19 Monoclonal Antibodies
Released on 4/25/18
Expires on 4/25/19
Emerging Strategies in the Diagnosis, Treatment and the Concept of Treatment-free Remission in Chronic Myeloid Leukemia
Released on 12/28/17
Expires on 12/28/18
Changing Landscape of Novel Combination Therapies for Patients with Newly Diagnosed, Risk Stratified and Relapsed/Refractory Multiple Myeloma
Released on 12/20/17
Expires on 12/20/18
Emerging Checkpoint Inhibitor and Combination Based Therapies for Relapsed or Refractory Hodgkin's Lymphoma
Released on 12/20/17
Expires on 12/20/18
Update on Treatment Options for Leukemia: Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia
Released on 11/30/17
Expires on 11/30/18
Novel Therapeutic Approaches of EGFR-, ALK-rearranged Targeted Therapies and Immunotherapy of Lung Cancer
Released on 10/6/17
Expires on 10/6/18
Emerging Strategies in Targeted Therapy of Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Released on 9/13/17
Expires on 9/13/18
Emerging Treatment Option with CDK 4/6 Inhibitors for Hormone Receptor-positive Breast Cancer: Insight into Clinical Activity and Safety Profile
Released on 8/8/17
Expires on 8/8/18
6th Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia
Released on 7/28/17
Expires on 7/28/18
Emerging Strategies in the Treatment of Metastatic Urothelial Bladder Carcinoma: Outlook for 2017
Released on 7/26/17
Expires on 7/26/18
Emerging Treatment Options for Metastatic Renal Cell Carcinoma
Released on 5/11/17
Expires on 5/11/18
Changing Paradigms in the Diagnosis and Treatment of Multiple Myeloma
Released on 3/10/2017
Expired on 3/10/2018
Update on Immunotherapy Options for Non-Small Cell Lung Cancer
Released on 3/6/17
Expires on 3/6/18
Practice Changing Shift in Treatment Strategies for Advanced Soft Tissue Sarcoma, Liposarcoma and Leiomyosarcoma
Released on 2/16/17
Expires on 2/16/18
Practice Changing Treatment with CDK 4/6 Inhibitors for Hormone Receptor‐Positive Breast Cancer
Released on 12/30/16
Expires on 12/30/17
Emerging Strategies in Treatment of Hodgkin Lymphoma and Non‐Hodgkin Lymphoma
Released on 12/29/16
Expires on 12/29/17
Emerging Immunotherapy Options for Relapsed or Refractory Hodgkin's Lymphoma
Released on 12/20/16
Expires on 12/20/17
Novel Therapeutic Approaches for Patients with Squamous Cell Carcinoma of the Head and Neck
Released on 11/15/16
Expires on 11/15/17
Novel Treatment Approaches for Non-Small-Cell Lung Cancer: A 2016 Update
Released on 10/25/16
Expires on 10/25/17
Novel Therapeutic Options for Acute Lymphoblastic Leukemia
Released on 7/21/16
Expires on 7/21/17
Advances in the Treatment Options for Liposarcoma/Leiomyosarcoma and Soft Tissue Sarcoma
Released on 7/21/16
Expires on 7/21/17
Novel Therapies for Malignant Melanoma: Immune Checkpoint Inhibitors, Targeted BRAF Inhibitors and Oncolytic Viral Therapy Approaches
Released on 7/7/16
Expires on 7/7/17
Emerging Strategies in the Treatment of Chronic Lymphocytic Lymphoma
Released on 7/1/16
Expires on 7/7/17
Personalized, Genotype-directed Therapy for Advanced Non-Small Cell Lung Cancer
Released on 6/30/2016
Expires on 6/30/2017
Changing Landscape in the Treatment of Metastatic Renal Cell Carcinoma and Bladder Cancer: Newer Insights
Released on 6/30/2016
Expires on 6/30/2017
Molecular Prognostic and Predictive Biomarkers Based Targeted Treatment of Colorectal Cancer
Released on 6/30/2016
Expires on 6/30/2017
5th Annual Symposium on Current Strategies in the Management of B-cell Lymphomas, T-cell Lymphomas, Multiple Myeloma and Leukemia
Released on 6/27/2016
Expires on 6/27/2016Changing Landscape of Treatment Options for Metastatic Urothelial Carcinoma
Released on 5/22/19
Expires on 5/22/20
New Paradigms in the Treatment of Relapsed Multiple Myeloma
Released on 5/3/20
Expires on 5/3/21
New Paradigms in the Treatment Options for Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML): European Perspective
Released on 4/28/20
Expires on 4/28/21
Current and Emerging Treatment Options for Lung Cancer and Head & Neck Carcinoma
Released on 12/30/19
Expires on 12/30/20
Changing Landscape of Treatment of HR+ and HER2- Metastatic Breast Cancer with PI3K and CDK 4/6 Inhibitors
Released on 12/26/19
Expires on 12/26/20
Changing Landscape of Treatment Options for ALL with CD19, CD22 Monoclonal Antibodies and AML with IDH1/2, FLT3, CD33 and Hedgehog Pathway Targeted Agents
Released on 9/17/19
Expires on 9/17/20
Evolving Landscape of Treatment for Hepatocellular Carcinoma with Multi-Targeted Tyrosine Kinase Inhibitors and Immunotherapy
Released on 6/24/19
Expires on 6/24/20
Changing Landscape of Targeted and Immunotherapies for Genitourinary Cancers
Released on 6/12/19
Expires on 6/12/20
Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma with Anti-PD-1/PD-L1 Agents
Released on 6/10/19
Expires on 6/10/20
New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia
Released on 5/13/19
Expires on 5/13/20
Optimizing Outcomes in Patients with Malignant Melanoma Treated with Targeted Agents, Checkpoint Inhibitors and Oncolytic Viral Therapies
Released on 12/30/18
Expires on 12/30/19
Emerging Novel PI3K Inhibitors, Anti-CD20 mAb and Combination Therapy Options for Follicular Lymphoma
Released on 12/30/18
Expires on 12/30/19
Changing Landscape of Treatment Strategies of TKI Interruptions, Discontinuations and Switching in Patients with Chronic Myeloid Leukemia
Released on 12/30/18
Expires on 12/30/19
Update on Treatment Options for Acute Lymphoblastic Leukemia with An Emphasis on CD19, CD22 Monoclonal Antibodies and Anti-CD19 CAR T-cell Therapy
Released on 12/30/18
Expires on 12/30/19
Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer
Released on 11/7/18
Expires on 11/7/19
Emerging Treatment Options for Genomic Subgroups of Acute Myeloid Leukemia with IDH1/2, FLT3 and CD33 Targeted Agents
Released on 10/19/18
Expires on 10/19/19
Emerging Strategies in Novel Targeted Therapies for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Bladder Carcinoma)
Released on 9/28/18
Expires on 9/28/19
Emerging Novel Anti-CD20 mAb, PI3K Inhibitors and Combination Therapy Options for Follicular Lymphoma
Released on 8/15/18
Expires on 8/15/19
Mapping the Future Treatment Options with Multitargeted TKIs and Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma
Released on 8/15/18
Expires on 8/15/19
Mapping the Current and Future Treatment Options for Advanced Soft Tissue Sarcoma Including Liposarcoma and Leiomyosarcoma
Released on 8/15/18
Expires on 8/15/19
7th Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia
Released on 7/2/18
Expires on 7/2/19
Immunotherapy with Anti-PD-1/PD-L1 Agents Are New Effective Therapies for Recurring and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Released on 6/29/18
Expires on- 6/29/19
Advances in the Treatment of Acute Lymphoblastic Leukemia with An Emphasis on CD22 and CD19 Monoclonal Antibodies
Released on 4/25/18
Expires on 4/25/19
Emerging Strategies in the Diagnosis, Treatment and the Concept of Treatment-free Remission in Chronic Myeloid Leukemia
Released on 12/28/17
Expires on 12/28/18
Changing Landscape of Novel Combination Therapies for Patients with Newly Diagnosed, Risk Stratified and Relapsed/Refractory Multiple Myeloma
Released on 12/20/17
Expires on 12/20/18
Emerging Checkpoint Inhibitor and Combination Based Therapies for Relapsed or Refractory Hodgkin's Lymphoma
Released on 12/20/17
Expires on 12/20/18
Update on Treatment Options for Leukemia: Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia
Released on 11/30/17
Expires on 11/30/18
Novel Therapeutic Approaches of EGFR-, ALK-rearranged Targeted Therapies and Immunotherapy of Lung Cancer
Released on 10/6/17
Expires on 10/6/18
Emerging Strategies in Targeted Therapy of Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Released on 9/13/17
Expires on 9/13/18
Emerging Treatment Option with CDK 4/6 Inhibitors for Hormone Receptor-positive Breast Cancer: Insight into Clinical Activity and Safety Profile
Released on 8/8/17
Expires on 8/8/18
6th Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia
Released on 7/28/17
Expires on 7/28/18
Emerging Strategies in the Treatment of Metastatic Urothelial Bladder Carcinoma: Outlook for 2017
Released on 7/26/17
Expires on 7/26/18
Emerging Treatment Options for Metastatic Renal Cell Carcinoma
Released on 5/11/17
Expires on 5/11/18
Changing Paradigms in the Diagnosis and Treatment of Multiple Myeloma
Released on 3/10/2017
Expired on 3/10/2018
Update on Immunotherapy Options for Non-Small Cell Lung Cancer
Released on 3/6/17
Expires on 3/6/18
Practice Changing Shift in Treatment Strategies for Advanced Soft Tissue Sarcoma, Liposarcoma and Leiomyosarcoma
Released on 2/16/17
Expires on 2/16/18
Practice Changing Treatment with CDK 4/6 Inhibitors for Hormone Receptor‐Positive Breast Cancer
Released on 12/30/16
Expires on 12/30/17
Emerging Strategies in Treatment of Hodgkin Lymphoma and Non‐Hodgkin Lymphoma
Released on 12/29/16
Expires on 12/29/17
Emerging Immunotherapy Options for Relapsed or Refractory Hodgkin's Lymphoma
Released on 12/20/16
Expires on 12/20/17
Novel Therapeutic Approaches for Patients with Squamous Cell Carcinoma of the Head and Neck
Released on 11/15/16
Expires on 11/15/17
Novel Treatment Approaches for Non-Small-Cell Lung Cancer: A 2016 Update
Released on 10/25/16
Expires on 10/25/17
Novel Therapeutic Options for Acute Lymphoblastic Leukemia
Released on 7/21/16
Expires on 7/21/17
Advances in the Treatment Options for Liposarcoma/Leiomyosarcoma and Soft Tissue Sarcoma
Released on 7/21/16
Expires on 7/21/17
Novel Therapies for Malignant Melanoma: Immune Checkpoint Inhibitors, Targeted BRAF Inhibitors and Oncolytic Viral Therapy Approaches
Released on 7/7/16
Expires on 7/7/17
Emerging Strategies in the Treatment of Chronic Lymphocytic Lymphoma
Released on 7/1/16
Expires on 7/7/17
Personalized, Genotype-directed Therapy for Advanced Non-Small Cell Lung Cancer
Released on 6/30/2016
Expires on 6/30/2017
Changing Landscape in the Treatment of Metastatic Renal Cell Carcinoma and Bladder Cancer: Newer Insights
Released on 6/30/2016
Expires on 6/30/2017
Molecular Prognostic and Predictive Biomarkers Based Targeted Treatment of Colorectal Cancer
Released on 6/30/2016
Expires on 6/30/2017
5th Annual Symposium on Current Strategies in the Management of B-cell Lymphomas, T-cell Lymphomas, Multiple Myeloma and Leukemia
Released on 6/27/2016
Expires on 6/27/2016